Fluorodopa

Summary

Fluorodopa (CHEMBL3547132) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 215.18 Da · C9H10FNO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3547132
Name	Fluorodopa
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	107730
ChEBI	CHEBI:49163
Molecular formula	C9H10FNO4
Molecular weight	215.18
InChIKey	PAXWQORCRCBOCU-LURJTMIESA-N

SMILES: C1=C(C(=CC(=C1O)O)F)C[C@@H](C(=O)O)N

IUPAC name: (2S)-2-amino-3-(2-fluoro-4,5-dihydroxyphenyl)propanoic acid

ChEBI definition: A non-proteinognic L-α-amino acid that is L-alanine in which one of the hydrogens of the methyl group has been replaced by a 2-fluoro-4,5-dihydroxyphenyl group.

Parent form; salt/anhydrous children: CHEMBL3400972

Patent coverage: 31 distinct patent families (91 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).